Non-infectious Pulmonary Diseases and HIV

Current HIV/AIDS Reports

Volumn 13, Issue 3, 2016, Pages 140-148

  Triplette, M ^a   Crothers, K ^a   Attia, E F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiretroviral therapy; ART; Chronic obstructive pulmonary disease; Complications; Genetic predisposition; Pulmonary complications; Pulmonary disease; Review

Indexed keywords

CARBOPLATIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; PACLITAXEL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; EMPHYSEMA; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; LOW INCOME COUNTRY; LUNG CANCER; LUNG DIFFUSION CAPACITY; LUNG DISEASE; MIXED INFECTION; NONHUMAN; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SMOKING; SURVIVAL TIME; COMPLICATION; GENETICS; IMMUNOLOGY; LUNG; LUNG TUMOR; PATHOPHYSIOLOGY; RISK FACTOR; VIROLOGY;

ANTI-HIV AGENTS; COINFECTION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; LUNG; LUNG NEOPLASMS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 84975747859     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-016-0313-0     Document Type: Review

References (101)

1. Davis JL, Fei M, Huang L. Respiratory infection complicating HIV infection. Curr Opin Infect Dis. 2008;21:184–90.
2. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383–8.
3. Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130:1326–33.
4. Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med. 2010;182:790–6.
5. Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J. 2015;46:1781–95.
6. Kirk GD, Merlo C, O’Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103–10.
7. Robbins HA, Pfeiffer RM, Shiels MS, et al. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015;107. 10.1093/jnci/dju503. Print 2015 Apr.
8. Staitieh B, Guidot DM. Noninfectious pulmonary complications of human immunodeficiency virus infection. Am J Med Sci. 2014;348:502–11.
9. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51:957–62.
10. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507–18.
11. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26:1017–25. The authors examined a large cohort of 37,294 HIV-infected Veterans compared to 75,750 uninfected Veterans with excellent follow-up to compare the incidence of lung cancer. In models adjusted for smoking and other potential confounding factors, they estimated the adjusted incidence rate ratio of lung cancer associated with HIV to be 1.7 95% CI:(1.5–1.9), suggesting an independent risk of lung cancer in HIV.
12. Winstone TA, Man SF, Hull M, et al. Epidemic of lung cancer in patients with HIV infection. Chest. 2013;143:305–14.
13. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153:452–60.
14. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9.
15. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306–15.
16. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458–65.
17. Hessol NA, Martinez-Maza O, Levine AM, et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS. 2015;29:1183–93.
18. Collini P, Morris A. Maintaining lung health with longstanding HIV. Curr Opin Infect Dis. 2016;29:31–8.
19. Kawabata S, Heredia A, Gills J, et al. Impact of HIV on lung tumorigenesis in an animal model. AIDS. 2015;29:633–5.
20. Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187. 2407-9-187.
21. Bruyand M, Le Marec F, Lavole A, et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS. 2015;29:1105–9.
22. Bruyand M, Ryom L, Shepherd L, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D:A:D study. J Acquir Immune Defic Syndr. 2015;68:568–77.
23. Team NLSTR, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
24. Sigel K, Wisnivesky J, Shahrir S, et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS. 2014;28:1007–14.
25. Hulbert A, Hooker CM, Keruly JC, et al. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol. 2014;9:752–9.
26. Makinson A, Eymard-Duvernay S, Raffi F, et al. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. AIDS. 2016;30:573–82. The risks and benefits of lung cancer screening were assessed in this single arm trial of chest CT in a subset of HIV-infected smokers in France. Patients were eligible for enrollment if they were older than 40, had a smoking history of at least 20 pack-years and had a CD4 cell count below 350. 442 patients were enrolled and underwent chest CT with ultimate prevalence of lung cancer of 2.03% (95% CI: 0.90-3.80) translating to a number needed to screen of 49 (95% CI: 26-111). No serious adverse events from procedures related to screening were reported. This suggests a possible benefit of screening for lung cancer in a subset of HIV-infected patients.
27. Shcherba M, Shuter J, Haigentz Jr M. Current questions in HIV-associated lung cancer. Curr Opin Oncol. 2013;25:511–7.
28. Brugnaro P, Morelli E, Cattelan F, et al. Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: epidemiology and outcome after two decades of HAART era. World J Virol. 2015;4:209–18.
29. Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015;24:1167–73.
30. Suneja G, Shiels MS, Angulo R, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32:2344–50.
31. Coghill AE, Shiels MS, Suneja G, et al. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83. This large cohort study, linking HIV/AIDS and cancer registries in 6 states, determined differences in cancer-specific mortality by HIV status. After adjustment for demographic features, cancer stage and diagnosis year, among those with lung cancer the estimated hazard ratio for cancer specific mortality was 1.28 (95% CI 1.17-1.39) comparing HIV-infected to uninfected patients. This suggests higher lung cancer-specific mortality in HIV, although it is unclear if this would persist with finer adjustment for other confounding variables.
32. Rengan R, Mitra N, Liao K, et al. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol. 2012;13:1203–9.
33. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
34. Thun M, Peto R, Boreham J, et al. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21:96–101.
35. World Health Organization, Tobacco Free Initiative. WHO report of the global tobacco epidemic, 2015, 2015. Available at http://www.who.int/tobacco/global_report/2015/en/.
36. Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med. 2011;62:157–70.
37. Petoumenos K, Hui E, Kumarasamy N, et al. Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc. 2010;13:51. 2652-13-51.
38. Mutyaba I, Phipps W, Krantz EM, et al. A Population-level evaluation of the effect of antiretroviral therapy on cancer incidence in Kyadondo County, Uganda, 1999–2008. J Acquir Immune Defic Syndr. 2015;69:481–6.
39. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006;118:985–90.
40. Jaquet A, Odutola M, Ekouevi DK, et al. Cancer and HIV infection in referral hospitals from four West African countries. Cancer Epidemiol. 2015;39:1060–5.
41. George MP, Kannass M, Huang L, et al. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One. 2009;4:e6328.
42. Samperiz G, Guerrero D, Lopez M, et al. Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy. HIV Med. 2014;15:321–9.
43. Makinson A, Hayot M, Eymard-Duvernay S, et al. High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers. Eur Respir J. 2015;45:828–31.
44. Gingo MR, Balasubramani GK, Rice TB, et al. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med. 2014;14:75. 2466-14-75.
45. Drummond MB, Kirk GD, Astemborski J, et al. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax. 2012;67:309–14.
46. Drummond MB, Merlo CA, Astemborski J, et al. The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS. 2013;27:1303–11.
47. Simonetti JA, Gingo MR, Kingsley L, et al. Pulmonary function in HIV-infected recreational drug users in the era of anti-retroviral therapy. J AIDS Clin Res. 2014;5:365.
48. Rahmanian SD, Wood KL, Lin S, et al. Gender differences in pulmonary function, respiratory symptoms, and macrophage proteomics among HIV-infected smokers. Scientifica (Cairo). 2014;2014:613689.
49. Gingo MR, Balasubramani GK, Kingsley L, et al. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One. 2013;8:e58812.
50. Kunisaki KM, Niewoehner DE, Collins G, et al. Pulmonary function in an international sample of HIV-positive, treatment-naive adults with CD4 counts >500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16 Suppl 1:119–28.
51. Popescu I, Drummond MB, Gama L, et al. Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190:744–55. This study examined markers of T-cell immunity in peripheral blood and bronchoalveolar lavage fluid using flow cytometry comparing HIV-infected patients with COPD to HIV-infected patients without COPD and uninfected patients with COPD. They found that lung mucosal CD4 T-cell deletion and HIV-specific lung mucosal immune dysregulation were associated with COPD in HIV, adding evidence that lung-specific immune dysfunction is related to the development of COPD in HIV.
52. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One. 2011;6:e16384.
53. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1073–80.
54. Cui L, Morris A, Huang L, et al. The microbiome and the lung. Ann Am Thorac Soc. 2014;11 Suppl 4:S227–32.
55. Cui L, Lucht L, Tipton L, et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am J Respir Crit Care Med. 2015;191:932–42. In this study, respiratory tract specimens from 56 patients were sequenced to examine the fungal microbiome comparing HIV-infected and uninfected subjects with and without COPD. There were significant differences in fungal communities in the lavage fluid by HIV and COPD status and over-representation of Pneumocystis jirovecii was observed in both these groups. This study suggests that alterations in the fungal microbiome may link lung dysfunction and HIV. Future studies of the microbiome in HIV-related COPD hold great promise to further elucidate the pathophysiology of chronic lung disease in this population.
56. Lozupone C, Cota-Gomez A, Palmer BE, et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med. 2013;187:1110–7.
57. Diaz PT, King MA, Pacht ER, et al. The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med. 1999;160:272–7.
58. Gingo MR, He J, Wittman C, et al. Contributors to diffusion impairment in HIV-infected persons. Eur Respir J. 2014;43:195–203.
59. Diaz PT, Wewers MD, Pacht E, et al. Respiratory symptoms among HIV-seropositive individuals. Chest. 2003;123:1977–82.
60. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369–72.
61. Crothers K, McGinnis K, Kleerup E, et al. HIV infection is associated with reduced pulmonary diffusing capacity. J Acquir Immune Defic Syndr. 2013;64:271–8.
62. Guaraldi G, Besutti G, Scaglioni R, et al. The burden of image based emphysema and bronchiolitis in HIV-infected individuals on antiretroviral therapy. PLoS One. 2014;9:e109027.
63. Petrache I, Diab K, Knox KS, et al. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax. 2008;63:463–9.
64. Attia EF, Akgun KM, Wongtrakool C, et al. Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4. Chest. 2014;146:1543–53.
65. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:71–86.
66. Besutti G, Raggi P, Zona S, et al. Independent association of subclinical coronary artery disease and emphysema in HIV-infected patients. HIV Med 2015.
67. Liu JC, Leung JM, Ngan DA, et al. Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease. PLoS One. 2015;10:e0124426.
68. Campo M, Oursler KK, Huang L, et al. Association of chronic cough and pulmonary function with 6-minute walk test performance in HIV infection. J Acquir Immune Defic Syndr. 2014;65:557–63.
69. Attia EF, McGinnis KA, Feemster LC, et al. Association of COPD with risk for pulmonary infections requiring hospitalization in HIV-infected veterans. J Acquir Immune Defic Syndr. 2015;70:280–8.
70. Lambert AA, Kirk GD, Astemborski J, et al. HIV infection is associated with increased risk for acute exacerbation of COPD. J Acquir Immune Defic Syndr. 2015;69:68–74.
71. Depp TB, McGinnis KA, Kraemer K, et al. Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. AIDS. 2016;30:455–63.
72. UNAIDS. How AIDS changed everything., 2015. Available at: http://www.unaids.org/en/resources/documents/2015/MDG6_15years-15lessonsfromtheAIDSresponse.
73. Finney LJ, Feary JR, Leonardi-Bee J, et al. Chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. Int J Tuberc Lung Dis. 2013;17:583–9.
74. Bloomfield GS, Khazanie P, Morris A, et al. HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S40–53.
75. Akanbi MO, Taiwo BO, Achenbach CJ, et al. HIV associated chronic obstructive pulmonary disease in Nigeria. J AIDS Clin Res. 2015;6:453.
76. Pefura-Yone EW, Fodjeu G, Kengne AP, et al. Prevalence and determinants of chronic obstructive pulmonary disease in HIV infected patients in an African country with low level of tobacco smoking. Respir Med. 2015;109:247–54.
77. Pacek LR, Cioe PA. Tobacco use, use disorders, and smoking cessation interventions in persons living with HIV. Curr HIV/AIDS Rep. 2015;12:413–20.
78. Isasti G, Moreno T, Perez I, et al. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29:231–4.
79. Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med. 2013;34:283–92.
80. Butrous G. Human immunodeficiency virus-associated pulmonary arterial hypertension: considerations for pulmonary vascular diseases in the developing world. Circulation. 2015;131:1361–70.
81. Tcherakian C, Couderc LJ, Humbert M, et al. Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension. Semin Respir Crit Care Med. 2013;34:645–53.
82. Feijoo MQ, Toro R, Lopez Vazquez de la Torre M, et al. Relationship between endothelin-1 levels and pulmonary arterial hypertension in HIV-infected patients. AIDS. 2014;28:2693–9.
83. Parikh RV, Scherzer R, Nitta EM, et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS. 2014;28:511–9.
84. George MP, Champion HC, Simon M, et al. Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013;48:374–81.
85. Dellegrottaglie S, Garcia-Alvarez A, Guarini P, et al. Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. Heart Lung. 2014;43:256–61.
86. Isiguzo GC, Okeahialam BN, Danbauchi SS, et al. Contributions of pulmonary hypertension to HIV-related cardiac dysfunction. Indian Heart J. 2013;65:644–9.
87. Dalvi P, Wang K, Mermis J, et al. HIV-1/cocaine induced oxidative stress disrupts tight junction protein-1 in human pulmonary microvascular endothelial cells: role of Ras/ERK1/2 pathway. PLoS One. 2014;9:e85246.
88. George MP, Champion HC, Gladwin MT, et al. Injection drug use as a “second hit” in the pathogenesis of HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2012;185:1144–6.
89. Spikes L, Dalvi P, Tawfik O, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med. 2012;185:1235–43.
90. Correale M, Palmiotti GA, Lo Storto MM, et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Invest. 2015;45:515–28.
91. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010;24:67–75.
92. Li Y, Li XH, Yu ZX, et al. HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension. Pulm Circ. 2015;5:538–46.
93. Amsellem V, Lipskaia L, Abid S, et al. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation. 2014;130:880–91. This study used a mouse model to explore the effect of CCR5, a receptor for cellular HIV entry present in both macrophages and vascular cells, on pulmonary arterial hypertension. The investigators used both gene disruption and pharmacologic methods (using the CCR5 antagonist maraviroc) to inactivate the CCR5 receptor. When exposed to hypoxic conditions, the CCR5 inactive mice demonstrated decreased inflammatory responses and proliferation of pulmonary artery smooth muscle, both of which are associated with the development of pulmonary hypertension. This study highlights the potential role of the CCR5 pathway in pulmonary hypertension and suggests a possible benefit of maraviroc in patients with HIV-associated pulmonary hypertension.
94. Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013;34:3538–46.
95. Bigna JJ, Sime PS, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment. AIDS Res Ther. 2015;12:36. 015-0078-3. eCollection 2015.
96. Syed FF, Sani MU. Recent advances in HIV-associated cardiovascular diseases in Africa. Heart. 2013;99:1146–53.
97. Chillo P, Bakari M, Lwakatare J. Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Afr. 2012;23:90–7.
98. Kolosionek E, Crosby A, Harhay MO, et al. Pulmonary vascular disease associated with schistosomiasis. Expert Rev Anti Infect Ther. 2010;8:1467–73.
99. Kolosionek E, King J, Rollinson D, et al. Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: detailed study. Pulm Circ. 2013;3:356–62.
100. Kariuki W, Manuel JI, Kariuki N, et al. HIV and smoking: associated risks and prevention strategies. HIV AIDS (Auckl). 2015;8:17–36.
101. Keith A, Dong Y, Shuter J, et al. Behavioral interventions for tobacco use in HIV-infected smokers: a meta-analysis. J Acquir Immune Defic Syndr 2016.